Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy
阿司匹林药物基因组学:PEAR1 在个性化抗血小板治疗中的作用
基本信息
- 批准号:8354496
- 负责人:
- 金额:$ 16.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-05 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAgonistAllelesAmishAntiplatelet DrugsAspirinBlood PlateletsCandidate Disease GeneCardiovascular DiseasesCardiovascular systemCessation of lifeClinicClinicalClinical ResearchClinical TrialsConfounding Factors (Epidemiology)Coronary arteryCoronary heart diseaseCoupledDNADevelopment PlansDoseEquilibriumEventFundingFutureGenesGeneticGenotypeGoalsHealthHeritabilityIndividualInterventionKnowledgeLife StyleMarylandMeasuresMedicineMentorsMinorMyocardial InfarctionOutcomeParticipantPatientsPharmaceutical PreparationsPharmacogenomicsPharmacotherapyPhysiciansPlatelet aggregationPrimary PreventionRandomizedReceptor AggregationRecruitment ActivityRegimenResearchResearch PersonnelResidual stateResistanceRiskRoleSecondary PreventionSingle Nucleotide PolymorphismStructureTranslatingTranslational ResearchUnited StatesUniversitiesVariantacute coronary syndromebasebiobankcareer developmentclinical applicationclopidogreldesignexperiencefollow-upgenome wide association studyhuman CYP2C19 proteinimprovedmortalitypatient orientedpatient oriented researchpercutaneous coronary interventionpreventprogramsprospectiverandomized trialresearch studyresponsestandard of caretrait
项目摘要
DESCRIPTION (provided by applicant): The purpose of this K23 application is to promote my career development in patient-oriented translational research and to facilitate successful transition into an independent investigator in the field of cardiovascular disease pharmacogenomics. Coronary heart disease (CHD) is the leading of mortality in the United States accounting for approximately 1 in 5 deaths. Aspirin as part of a dual antiplatelet therapy (DAPT) regimen significantly improves cardiovascular outcomes in patients with acute coronary syndrome and/or undergoing percutaneous coronary intervention (PCI). However, there is great interindividual variation in platelet response to aspirin, and patients with higher on-treatment platelet reactivity have increased risk of experiencing an ischemic event. This interindividual variation in response is the likely reason why the optimal dose of aspirin when used alone or in combination with other antiplatelet agents is highly controversial. While heritability estimates suggest that genetic factors are an important determinant of aspirin response, candidate gene approaches have failed to identify variants that are reproducibly associated with aspirin response. Recently, using a genome-wide association approach, we identified a common single nucleotide polymorphism (rs12041331) in the platelet endothelial aggregation receptor 1 (PEAR1) gene that contributes substantially to variability in platelet reactivity during DAPT. Furthermore, DAPT-treated PCI patients carrying the risk allele had a 2 to 4-fold decrease in survival at 1 year of follow-up, and aspirin-treated stable coronary artery patients had a 2-fold increase in the rate of myocardial infarction. These associations were not observed in the absence of aspirin administration. We hypothesize that PEAR1 genotype influences aspirin response and is a determinant of optimal aspirin dose. This project aims to: 1) assess the effect of aspirin dosing (81, 162, or 324 mg) on agonist-stimulated ex-vivo platelet aggregation by PEAR1 rs12041331 genotype in healthy Amish individuals (20 per genotype group), and 2) evaluate the interaction between PEAR1 rs12041331 genotype and aspirin dose (81 vs. 324 mg) on 1-year survival in approximately 1,400 PCI patients recruited as part of the PGRN-funded Pharmacogenomics of Anti-Platelet Intervention 2 (PAPI-2) Study. These studies will contribute to our knowledge regarding the genetic underpinnings and mechanisms underlying aspirin resistance as well as optimal aspirin dosing. Given the impact of aspirin therapy on primary and secondary prevention of adverse cardiovascular events, this study has important health implications since 20 - 60% of individuals carry at least 1 copy of the PEAR1 rs12041331 minor allele. Understanding drug response variability in patients taking anti- thrombotics is critical for optimizing cardiovascular pharmacotherapy and ultimately patient outcomes.
PUBLIC HEALTH RELEVANCE: Aspirin as part of a dual antiplatelet therapy regimen is the standard of care for preventing adverse cardiovascular outcomes in patients with acute coronary syndrome and/or undergoing percutaneous coronary intervention. Given the wide variability of platelet function and clinical outcomes in response to aspirin therapy, it is importnt to identify the factors that cause dose-response variability and to optimize antiplatelet treatment
based on knowledge of these factors. The proposed study will help guide physicians in choosing the most appropriate antiplatelet therapy in the context of PEAR1 genotype, a newly discovered and potentially important genetic contributor to aspirin resistance.
描述(由申请人提供):本 K23 申请的目的是促进我在以患者为导向的转化研究方面的职业发展,并促进成功过渡为心血管疾病药物基因组学领域的独立研究者。冠心病 (CHD) 是美国死亡率最高的疾病,约占死亡人数的五分之一。阿司匹林作为双重抗血小板治疗 (DAPT) 方案的一部分,可显着改善急性冠脉综合征和/或接受经皮冠状动脉介入治疗 (PCI) 患者的心血管结局。然而,血小板对阿司匹林的反应存在很大的个体差异,治疗中血小板反应性较高的患者发生缺血事件的风险增加。这种个体间的反应差异可能是阿司匹林单独使用或与其他抗血小板药物联合使用时的最佳剂量备受争议的原因。虽然遗传力估计表明遗传因素是阿司匹林反应的重要决定因素,但候选基因方法未能识别与阿司匹林反应可重复相关的变异。最近,利用全基因组关联方法,我们在血小板内皮聚集受体 1 (PEAR1) 基因中发现了一个常见的单核苷酸多态性 (rs12041331),该基因对 DAPT 期间血小板反应性的变异有很大影响。此外,携带风险等位基因的接受 DAPT 治疗的 PCI 患者在随访 1 年时生存率下降 2 至 4 倍,而接受阿司匹林治疗的稳定性冠状动脉患者的心肌梗塞发生率增加 2 倍。在不服用阿司匹林的情况下没有观察到这些关联。我们假设 PEAR1 基因型影响阿司匹林反应,并且是最佳阿司匹林剂量的决定因素。该项目旨在:1) 评估阿司匹林剂量(81、162 或 324 毫克)对健康阿米什人(每个基因型组 20 人)中 PEAR1 rs12041331 基因型激动剂刺激的离体血小板聚集的影响,2) 评估PEAR1 rs12041331 基因型与阿司匹林剂量之间的相互作用(81 vs. 324) mg)对大约 1,400 名 PCI 患者的 1 年生存率进行了研究,这些患者是 PGRN 资助的抗血小板干预药物基因组学 2 (PAPI-2) 研究的一部分。这些研究将有助于我们了解阿司匹林抵抗的遗传基础和机制以及最佳阿司匹林剂量。鉴于阿司匹林治疗对不良心血管事件一级和二级预防的影响,这项研究具有重要的健康意义,因为 20-60% 的个体携带至少 1 个 PEAR1 rs12041331 次要等位基因拷贝。了解服用抗血栓药物的患者的药物反应变异性对于优化心血管药物治疗和最终患者的治疗结果至关重要。
公共卫生相关性:阿司匹林作为双重抗血小板治疗方案的一部分,是预防急性冠脉综合征和/或接受经皮冠状动脉介入治疗患者不良心血管结局的护理标准。鉴于阿司匹林治疗反应中血小板功能和临床结果的广泛变异性,确定导致剂量反应变异性的因素并优化抗血小板治疗非常重要
基于对这些因素的了解。拟议的研究将有助于指导医生在 PEAR1 基因型的背景下选择最合适的抗血小板治疗,PEAR1 基因型是一种新发现的、可能是阿司匹林抵抗的重要遗传因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSHUA PATRICK LEWIS其他文献
JOSHUA PATRICK LEWIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSHUA PATRICK LEWIS', 18)}}的其他基金
Clinical and Nutrigenetic Assessment of Zinc in Patients with Prediabetes
糖尿病前期患者锌的临床和营养遗传学评估
- 批准号:
10713103 - 财政年份:2023
- 资助金额:
$ 16.12万 - 项目类别:
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy
羧酸酯酶 1 (CES1) 在个性化抗血小板治疗中的影响
- 批准号:
9364969 - 财政年份:2017
- 资助金额:
$ 16.12万 - 项目类别:
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy
羧酸酯酶 1 (CES1) 在个性化抗血小板治疗中的影响
- 批准号:
10191007 - 财政年份:2017
- 资助金额:
$ 16.12万 - 项目类别:
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy
阿司匹林药物基因组学:PEAR1 在个性化抗血小板治疗中的作用
- 批准号:
8539634 - 财政年份:2012
- 资助金额:
$ 16.12万 - 项目类别:
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy
阿司匹林药物基因组学:PEAR1 在个性化抗血小板治疗中的作用
- 批准号:
8908023 - 财政年份:2012
- 资助金额:
$ 16.12万 - 项目类别:
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy
阿司匹林药物基因组学:PEAR1 在个性化抗血小板治疗中的作用
- 批准号:
8723858 - 财政年份:2012
- 资助金额:
$ 16.12万 - 项目类别:
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy
阿司匹林药物基因组学:PEAR1 在个性化抗血小板治疗中的作用
- 批准号:
9128660 - 财政年份:2012
- 资助金额:
$ 16.12万 - 项目类别:
相似国自然基金
FOXD1-SFRP2及其特异性激动剂在骨关节炎中的功能及作用机制探究
- 批准号:82372438
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
脂质纳米粒体内介导嵌合抗原受体-M1型巨噬细胞协同TLR激动剂治疗实体瘤的研究
- 批准号:82304418
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TRPV4/SKCa信号轴在AMPK激动剂抑制微小动脉舒张作用中的机制研究
- 批准号:82304584
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向STING激动剂和TREM2抑制剂增强PD-1抑制剂对胰腺癌的抗肿瘤作用研究
- 批准号:82303740
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Effects of genetic differences and bilingual status on cognitive control
遗传差异和双语状态对认知控制的影响
- 批准号:
9002080 - 财政年份:2015
- 资助金额:
$ 16.12万 - 项目类别:
Central and Peripheral Roles of TREM2 in Alzheimer's Disease
TREM2 在阿尔茨海默病中的中枢和外周作用
- 批准号:
9001560 - 财政年份:2015
- 资助金额:
$ 16.12万 - 项目类别:
Signaling pathways that regulate scaling and regeneration of the cerebellum
调节小脑缩放和再生的信号通路
- 批准号:
8895646 - 财政年份:2015
- 资助金额:
$ 16.12万 - 项目类别:
Tlr1: Functional and Genetic Variation in Urinary Tract Infection
Tlr1:尿路感染的功能和遗传变异
- 批准号:
8649293 - 财政年份:2014
- 资助金额:
$ 16.12万 - 项目类别:
Tlr1: Functional and Genetic Variation in Urinary Tract Infection
Tlr1:尿路感染的功能和遗传变异
- 批准号:
8825335 - 财政年份:2014
- 资助金额:
$ 16.12万 - 项目类别: